Why is it in the news?
- The introduction of ‘InfexnTM’ marks a transformative shift in Kerala’s medical landscape as India’s first genomics-based infectious disease test, leveraging next-generation sequencing technology.
About InfexnTM
- InfexnTM is a state-of-the-art targeted next-generation sequencing test developed by IIT-Bombay-based HaystackAnalytics and NIMS Medicity at Neyyattinkara.
- The primary objective of InfexnTM is to detect bacterial and/or fungal infections, along with identifying relevant antimicrobial resistance genes, all within a timeframe of 24 hours.
Features:
- InfexnTM is a comprehensive kit-cum-software solution designed to be used within hospital settings.
- It is proudly labelled as a “Made in India, Made for the World” test, showcasing its indigenous development and global applicability.
Significance
- Empowerment of Healthcare Ecosystem: InfexnTM promises to empower the healthcare ecosystem with advanced and definitive diagnostics, thereby facilitating optimal antibiotic usage.
- Championing Antimicrobial Leadership: Its introduction aligns with the national goal of championing antimicrobial leadership, crucial for combating the rise of antimicrobial resistance.
- Enhanced Accuracy and Efficiency: InfexnTM’s innovative approach is expected to enhance the accuracy and efficiency of infectious disease detection, enabling timely and precise diagnosis.
- Improved Patient Outcomes: By providing clinicians with efficient and accurate diagnoses of infectious diseases, InfexnTM facilitates targeted therapy and ultimately leads to improved patient outcomes.
- Life-saving Potential: The timely generation of InfexnTM reports can be life-saving for patients with suspected infections, allowing for prompt initiation of appropriate treatment strategies.
